152 related articles for article (PubMed ID: 11397626)
1. In vitro activity of quinolones against isolates from paediatric urinary tract infections from three Venezuelan centres.
Rodríguez AJ; Rodríguez CN; Meijomil P; García A; Duque C; Molina N; Barbella R; Lakatos M; Bellorin E; Mendoza M
Int J Antimicrob Agents; 2001 Jun; 17(6):531-2. PubMed ID: 11397626
[No Abstract] [Full Text] [Related]
2. Association between fluoroquinolone resistance and resistance to other antimicrobial agents among Escherichia coli urinary isolates in the outpatient setting: a national cross-sectional study.
Hwang TJ; Hooper DC
J Antimicrob Chemother; 2014 Jun; 69(6):1720-2. PubMed ID: 24521853
[No Abstract] [Full Text] [Related]
3. Clinical implications. In vitro resistance of E coli to TMP/SMX.
Postgrad Med; 2001 Aug; 110(2 Suppl):11-5; discussion 26-7. PubMed ID: 19667571
[No Abstract] [Full Text] [Related]
4. Increasing in vitro resistance of E coli to TMP/SMX.
Postgrad Med; 2001 Aug; 110(2 Suppl):5-8; discussion 26-7. PubMed ID: 19667569
[No Abstract] [Full Text] [Related]
5. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Gualco L; Schito AM; Schito GC; Marchese A
Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and risk factors for fosfomycin resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection.
Ramos J; Bastida MT; Niño E; Smithson A
Enferm Infecc Microbiol Clin (Engl Ed); 2019; 37(7):484-485. PubMed ID: 30075982
[No Abstract] [Full Text] [Related]
8. In vitro resistance of E coli to TMP/SMX and clinical failure.
Postgrad Med; 2001 Aug; 110(2 Suppl):9-10; discussion 26-7. PubMed ID: 19667570
[No Abstract] [Full Text] [Related]
9. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection.
Farrell DJ; Morrissey I; De Rubeis D; Robbins M; Felmingham D
J Infect; 2003 Feb; 46(2):94-100. PubMed ID: 12634070
[TBL] [Abstract][Full Text] [Related]
10. Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands.
Goettsch W; van Pelt W; Nagelkerke N; Hendrix MG; Buiting AG; Petit PL; Sabbe LJ; van Griethuysen AJ; de Neeling AJ
J Antimicrob Chemother; 2000 Aug; 46(2):223-8. PubMed ID: 10933644
[TBL] [Abstract][Full Text] [Related]
11. [Quinolone resistance of Escherichia coli strains isolated from urinary tract infections].
Agulla A; Montes I
Enferm Infecc Microbiol Clin; 1994; 12(6):322. PubMed ID: 8080877
[No Abstract] [Full Text] [Related]
12. Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections.
Pérez-Trallero E; Urbieta M; Jimenez D; García-Arenzana JM; Cilla G
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):349-51. PubMed ID: 8354301
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in Germany.
Kresken M; Körber-Irrgang B
Antimicrob Agents Chemother; 2014 Nov; 58(11):7019-20. PubMed ID: 25182654
[No Abstract] [Full Text] [Related]
14. [The role of modern aminoglycosides in urological practice].
Derevianko II
Urologiia; 2004; (6):16-9. PubMed ID: 15719723
[No Abstract] [Full Text] [Related]
15. The changing pattern of antimicrobial resistance within 42,033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999-2009.
Cullen IM; Manecksha RP; McCullagh E; Ahmad S; O'Kelly F; Flynn RJ; McDermott T; Murphy P; Grainger R; Fennell JP; Thornhill JA
BJU Int; 2012 Apr; 109(8):1198-206. PubMed ID: 21883861
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).
Zhanel GG; Hisanaga TL; Laing NM; DeCorby MR; Nichol KA; Palatnik LP; Johnson J; Noreddin A; Harding GK; Nicolle LE; Hoban DJ;
Int J Antimicrob Agents; 2005 Nov; 26(5):380-8. PubMed ID: 16243229
[TBL] [Abstract][Full Text] [Related]
17. The role of clinical guidelines.
Postgrad Med; 2001 Aug; 110(2 Suppl):16-20; discussion 26-7. PubMed ID: 19667572
[No Abstract] [Full Text] [Related]
18. New uses for new and old quinolones and the challenge of resistance.
Hooper DC
Clin Infect Dis; 2000 Feb; 30(2):243-54. PubMed ID: 10671323
[No Abstract] [Full Text] [Related]
19. Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections.
Cizman M; Orazem A; Krizan-Hergouth V; Kolman J
J Antimicrob Chemother; 2001 Apr; 47(4):502. PubMed ID: 11266434
[No Abstract] [Full Text] [Related]
20. Antimicrobial resistance of Escherichia coli isolated from urine in Thailand from 2000 to 2005.
Polwichai P; Dejsirilert S; Panpetch S; Sawanpanyalert P; Aswapokee N; Mootsikapun P
J Med Assoc Thai; 2009 Aug; 92 Suppl 4():S59-67. PubMed ID: 21298846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
